| Biological Information | |
|---|---|
| Background Information: | ActRIIB (Activin receptor type-2B) is a type II transmembrane serine/threonine kinase receptor that is involved in the signaling of members of the TGF-β superfamily of cytokines, including activin, myostatin, and growth and differentiation factor 11 (GDF11). ActRIIB signaling has been shown to inhibit muscle growth and promote muscle wasting through the activation of the Smad2/3 signaling pathway and the subsequent repression of muscle-specific genes.
Research has suggested that targeting ActRIIB signaling may be a potential therapeutic strategy for the treatment of muscle wasting diseases, such as sarcopenia, cachexia, and muscular dystrophy. Several drugs targeting ActRIIB signaling, including the myostatin inhibitors and selective androgen receptor modulators (SARMs), are currently in clinical development as potential therapies for these conditions. |
| Target Class: | Kinase |
| Accession Number: | NM_001106.3 |
| Target Name: | ActRIIB |
| Target Aliases: | ACVR2B, Activin A Receptor Type 2B, Activin Receptor Type-2B, HTX4 |
| Target Species: | Human |
| Usage | |
| Product Type: | Enzymes |
| Application: | Drug Discovery & Development |
| Storage Conditions: | 1 year at -70°C |
| Usage Disclaimer: | These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information. |
ActRIIB, active
10 µg of active ActRIIB. N-Terminal GST-tagged, recombinant, human ActRIIB amino acids 185-488.
Datasheets
16-052x Datasheet
View Document